Core Viewpoint - Zhaoke Ophthalmology-B (06622) has seen a stock price increase of over 7% following the announcement of a distribution and supply agreement with PT Ferron Par Pharmaceuticals for its innovative drug BRIMOCHOL™ PF, aimed at treating presbyopia in the Indonesian market [1] Company Developments - Zhaoke Ophthalmology has signed a distribution and supply agreement with PT Ferron, a leading pharmaceutical company in Indonesia, granting exclusive rights for the import, promotion, distribution, marketing, and sale of BRIMOCHOL™ PF in Indonesia [1] - The agreement includes an upfront payment to Zhaoke Ophthalmology, along with potential milestone payments based on certain achievements [1] Product Information - BRIMOCHOL™ PF is an innovative drug developed for the treatment of presbyopia, with its rights licensed from Tenpoint Therapeutics, Ltd. [1] - Tenpoint Therapeutics has submitted a new drug application to the U.S. Food and Drug Administration (FDA), with the Prescription Drug User Fee Act (PDUFA) date set for January 28, 2026 [1]
港股异动 | 兆科眼科-B(06622)涨超7% 与印尼药企PT Ferron就分销老花眼药达成协议